Performance of the recommended ESC/EASD cardiovascular risk strati�cation model and SCORE in comparison to NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus
暂无分享,去创建一个
[1] Akshay S. Desai,et al. NT‐proBNP by Itself Predicts Death and Cardiovascular Events in High‐Risk Patients With Type 2 Diabetes Mellitus , 2020, Journal of the American Heart Association.
[2] A. Peters,et al. Biomarker-defined pathways for incident type 2 diabetes and coronary heart disease—a comparison in the MONICA/KORA study , 2020, Cardiovascular Diabetology.
[3] M. Budoff,et al. N-terminal Pro B-type Natriuretic Peptide and High-sensitivity Cardiac Troponin as Markers for Heart Failure and Cardiovascular Disease Risks According to Glucose Status (from the Multi-Ethnic Study of Atherosclerosis [MESA]). , 2020, The American journal of cardiology.
[4] C. Cannon,et al. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial , 2020, Journal of the American Heart Association.
[5] P. Sham,et al. High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus , 2019, Cardiovascular Diabetology.
[6] G. Filippatos,et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.
[7] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[8] Thomas Kahan,et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.
[9] Akshay S. Desai,et al. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes , 2018, European journal of heart failure.
[10] T. Einarson,et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 , 2018, Cardiovascular Diabetology.
[11] S. Solomon,et al. Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus , 2017, Journal of the American Heart Association.
[12] V. Z. Rocha,et al. Cardiovascular risk assessment in patients with diabetes , 2017, Diabetology & Metabolic Syndrome.
[13] Deepak L. Bhatt,et al. Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. , 2016, JAMA cardiology.
[14] M. Gheorghiade,et al. Prognostic role of N-terminal pro-brain natriuretic peptide in asymptomatic hypertensive and diabetic patients in primary care: impact of age and gender , 2016, Clinical Research in Cardiology.
[15] Jennifer Y. Liu,et al. Diabetes and Prior Coronary Heart Disease are Not Necessarily Risk Equivalent for Future Coronary Heart Disease Events , 2016, Journal of General Internal Medicine.
[16] S. Solomon,et al. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 2016, Diabetes Care.
[17] F. Agakov,et al. Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes , 2015, Diabetologia.
[18] N. Sattar,et al. N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study , 2014, Diabetologia.
[19] M. Woodward,et al. Response to Comment on Hillis et al. The Relative and Combined Ability of High-Sensitivity Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Predict Cardiovascular Events and Death in Patients With Type 2 Diabetes. Diabetes Care 2014;37:295–303 , 2014, Diabetes Care.
[20] R. Prager,et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. , 2013, Journal of the American College of Cardiology.
[21] C. Watson,et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. , 2013, JAMA.
[22] N. J. Wareham,et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review , 2009, Diabetologia.
[23] M. Gheorghiade,et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. , 2009, Journal of cardiac failure.
[24] I. Idris,et al. Is diabetes a coronary risk equivalent? Systematic review and meta‐analysis , 2009, Diabetic medicine : a journal of the British Diabetic Association.
[25] R. Prager,et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. , 2008, European heart journal.
[26] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[27] Y. Pinto,et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. , 2007, Archives of internal medicine.
[28] A. Dyer,et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. , 2003, JAMA.
[29] A. Dyer,et al. Major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events , 2003 .
[30] H. Tunstall-Pedoe,et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.
[31] R. Klein,et al. The relation of atherosclerotic cardiovascular disease to retinopathy in people with diabetes in the Cardiovascular Health Study , 2002, The British journal of ophthalmology.
[32] R. Beaglehole,et al. The real contribution of the major risk factors to the coronary epidemics: time to end the "only-50%" myth. , 2001, Archives of internal medicine.
[33] T. Hillier,et al. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. , 2001, Diabetes care.
[34] M. Taskinen,et al. ESC/EAS Guidelines for the Management of Dyslipidaemias , 2013 .
[35] Michael H. Olsen,et al. ESH / ESC Guidelines for the management of arterial hypertension , 2013 .
[36] H. Hammes,et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD , 2013 .
[37] E. Giannitsis,et al. Multicentre analytical evaluation of a new point-of-care system for the determination of cardiac and thromboembolic markers. , 2010, Clinical laboratory.
[38] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice , 2004 .
[39] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[40] H. Parving,et al. O R I G I N a L I N V E S T I G a T I O N Open Access , 2022 .